Pharmaxis Ltd
ASX:PXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmaxis Ltd
Total Equity
Pharmaxis Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmaxis Ltd
ASX:PXS
|
Total Equity
AU$9.6m
|
CAGR 3-Years
88%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Equity
-AU$18.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$370.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$338.5m
|
CAGR 3-Years
101%
|
CAGR 5-Years
69%
|
CAGR 10-Years
37%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Equity
AU$90.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Total Equity
AU$9.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Pharmaxis Ltd
Glance View
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.
See Also
What is Pharmaxis Ltd's Total Equity?
Total Equity
9.6m
AUD
Based on the financial report for Jun 30, 2023, Pharmaxis Ltd's Total Equity amounts to 9.6m AUD.
What is Pharmaxis Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-3%
Over the last year, the Total Equity growth was -12%. The average annual Total Equity growth rates for Pharmaxis Ltd have been 88% over the past three years , -3% over the past five years .
